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Abstract
The protegrin PG-1, belonging to the family of L-stranded antimicrobial peptides, exerts its activity by forming pores in the
target biological membranes. Linear analogues derived from PG-1 do not form pores in the phospholipid membranes and
have been used successfully to deliver therapeutic compounds into eucaryotic cells. In this paper, the translocation of PG-1
and of a linear analogue through artificial phospholipid membranes was investigated, leading to a possible mechanism for the
activity of these peptidic vectors. We report here that [12W]PG-1, a fluorescent analogue of PG-1, is able to translocate
through lipid bilayers and we demonstrate that this property depends on its secondary structure. Our results agree with the
recent mechanism proposed for the translocation and permeabilisation activities of several helical and L-stranded peptides. In
addition, our data corroborate recent work suggesting that certain protegrin-derived vectors enter into endothelial cells by
adsorptive-mediated endocytosis. ß 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Protegrin-1 (PG-I) is an 18-amino-acid peptide iso-
lated originally from porcine leucocyte cells [1]. This
peptide displays a broad-range antimicrobial activity
spectrum [1^3] and has, therefore, excellent potential
for pharmaceutical uses. The structure of PG-1 in
solution as determined by nuclear magnetic reso-
nance (NMR) studies is a one-turn L-hairpin in
which two antiparallel strands linked by a L-turn
are stabilised by two disulphide bridges [4,5]. The
cationic nature of the peptide allows its interaction
with the lipid matrix of bacterial membranes contain-
ing negatively charged lipids, but its antimicrobial
activity itself depends on its ability to form pores
in these membranes. Several studies have demon-
strated that PG-1 is able to alter the permeability
of cellular membranes [6] or of arti¢cial bilayers
[7]. Structural investigations by NMR have indicated
that this peptide should adopt a dimeric structure in
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a membrane-mimetic environment supporting a
model in which the association of several dimers re-
sults in the formation of a pore [8]. In addition,
recent work has provided evidence of the existence
of two di¡erent states of PG-1 in a lipid bilayer, one
corresponding to its parallel orientation on the sur-
face of the membrane and the other corresponding to
its transmembranal insertion [9,10].
It has been shown previously that disulphide
bridges of protegrin are a prerequisite for its pore
formation capability [6]. The linearisation of this
peptide o¡ered the possibility of designing analogues
able to interact with the cell surface but lacking the
membrane-disrupting activity. One of these peptides,
SynB1, was shown to enhance the uptake of doxo-
rubicin into cultured multidrug-resistant K562 cells
[11] and to increase its transport across the blood^
brain barrier in mouse and rat [12,13]. Other vectors,
belonging to di¡erent cell-permeable peptide families,
have been developed recently for the intracellular
delivery of therapeutic compounds in vitro and in
vivo (see for review [14] and references therein).
However, questions were raised about their mode
of entry into cells, which does not seem to be via
classic endocytosis [14]. For several cell-permeable
peptides, it was proposed that they cross the lipid
matrix of plasma membranes in an energy-independ-
ent manner to penetrate into cells [15,16].
We investigated the ability of a £uorescent ana-
logue of PG-1 and of a £uorescent linear analogue
to translocate from the outer to the inner lea£et of a
membrane. It was demonstrated previously that the
antimicrobial peptide tachyplesin I (TA-1), having a
secondary structure similar to that of PG-1 [17], is
able to form transient anionic-selective pores and to
translocate through phospholipid bilayers [18]. This
pore formation^translocation mechanism also con-
cerns natural helical peptides such as magainin [19],
mellitin [20] and mastoparan-X [21]. However, no
data related to the translocation ability of PG-1
have yet been reported.
We demonstrate here by £uorescence spectroscopy
that PG-1, but not its linear analogue, crosses the
membrane of phospholipidic vesicles. In addition,
we show that the translocation ability of PG-1 is
coupled to its pore formation capacity and depends
on its folding in a L-hairpin. This suggests that pro-
tegrin-derived vectors do not spontaneously cross
the lipid matrix of plasma membranes to enter into
cells.
2. Materials and methods
Fmoc-PAL-PEG-PS (High Load) and 9-£uorenyl-
methyloxycarbonyl (Fmoc) amino acids were pur-
chased from Perseptive Biosystems (Hamburg, Ger-
many). Other reagents used for peptide synthesis
included N,NP-diisopropylcarbodiimide (DIPCDI,
Fluka), 1-hydroxybenzotriazole (HOBT, Perkin El-
mer), N,N-diisopropylethylamine (DIEA, Fluka),
benzotriazole-1-yl-oxy-tris-pyrrolidinophosphonium
hexa£uorophosphate (PyBop, Novabiochem) and di-
methylformamide (DMF, Perseptive Biosystems).
The lipid POPC (1-palmitoyl-2-oleyl-sn-glycero-3-
phosphocholine) and POPG (1-palmitoyl-2-oleyl-sn-
glycero-3-phosphoglycerol) were obtained from
Avanti Polar Lipids (AL, USA). NBD-PE (N-[7-ni-
trobenz-2-oxo-1,3-diazol-4-yl]dipalmitoyl]-L-K-phos-
phatidylethanolamine), DNS-PE (N-[5-(dimethylami-
no)-naphthyl]-1-sulfonyl]dipalmitoyl-L-K-phosphati-
dylethanolamine) and calcein were obtained from
Molecular Probes (Eugene, OR, USA). Sodium di-
thionite, 2,2,2-tri£uoroethanol (TFE) and sodium
dodecyl sulphate (SDS) were supplied by Sigma (St
Louis, MO, USA). Sephadex G75 was purchased
from Pharmacia Biotech (Uppsala, Sweden).
2.1. Peptide synthesis
The peptides were synthesised according to Fmoc-
tBu strategy using an AMS 422 (ABIMED, Ger-
many). After peptide elongation, resin was treated
with piperidine (20% in DMF) to deprotect the N-
terminus of peptide, washed with DMF and treated
with deprotecting mixture to cleave peptides from
resin and deprotect the side-chains. The labelling of
TMR-peptide was done in DMF by adding 5-(and-
6)-carboxytetramethylrhodamine to the amino-termi-
nal free peptide in presence of DIEA (2 eq) and
PyBop (1.5 eq). The cyclisation of PG-1 and
[12W]PG-1 by disulphide bridges was realised ac-
cording to the protocol of Tam et al. [22]. Peptide
puri¢cation was accomplished by reverse phase high
performance liquid chromatography (Water-prep LC
40, Water) under TFA 0,01%/acetonitrile gradient
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condition. Puri¢cation, as assessed by reverse phase
analytic chromatography (Beckman Gold equipped
with a Diode Array detector), was over 95% for
both peptides by the criterion of UV absorbance at
220, 280 and 540 nm when the peptides were labelled
with TMR. The molecular masses were validated by
MALDI-TOF spectrometry (Voyager Elite, Persep-
tive Biosystem, UK).
2.2. Vesicle preparation
For preparation of small unilamellar vesicles
(SUVs), a lipid ¢lm of the desired composition was
dried for 3 h and then suspended in bu¡er (20 mM
Tris, 150 mM NaF and 0.1 mM EDTA (pH 7.4)) to
give a ¢nal concentration between 25 and 30 mM.
The suspension was sonicated in ice-cold water for
25 min using a titanium tip ultrasonicator. Titanium
and lipid debris were removed by centrifugation at
100 000Ug. Dynamic light-scattering measurements
(Brookhaven Instruments, USA) con¢rmed the exis-
tence of a single population of vesicles (more than
95% of mass content) with a mean diameter of 31 þ 1
nm. For preparation of large unilamellar vesicles
(LUVs), the lipid suspension in bu¡er (20 mM
Tris, 150 mM NaCl and 1 mM EDTA (pH 7.4))
was freeze-thawed for ¢ve cycles and then extruded
through polycarbonate ¢lters (0.1 Wm pore size) 21
times. The lipid concentration was determined in du-
plicate by phosphorus analysis as described in [23].
2.3. Peptide binding
Fluorescence measurements were performed in 3-
ml quartz cells at 25 þ 0.1‡C under constant magnetic
stirring using a SLM AB-2 spectro£uorometer (SLM
Instruments, Urbana, IL, USA). For recording the
emission spectra of peptide, excitation was set at 280
nm. Both excitation and emission band-pass were set
at 4 nm. For each measure, the baseline spectra re-
corded in the absence of peptide were subtracted
from the peptide spectra.
2.4. Dye release
Dye-entrapped LUVs were prepared with a lipid
¢lm of desired composition by the use of 70 mM
calcein in bu¡er (pH was adjusted to 7.4 with 1 M
NaOH) as a hydrating solution. Calcein-entrapped
vesicles were separated from free calcein on a Sepha-
dex-G75 column (18U1 cm). The release of calcein
from LUVs was monitored by £uorescence at an
emission wavelength of 520 nm (excitation wave-
length of 490 nm). The maximum £uorescence inten-
sity corresponding to 100% leakage was determined
by the addition of 10 Wl of 10% w/v Triton X-100 to
3 ml of the sample. The apparent percent leakage
value was calculated according to 100U(F3F0)/
(Fmax3F0). F and Fmax correspond respectively to
the £uorescence intensity before and after the deter-
gent addition. F0 represents the £uorescence of the
intact vesicles. The temperature was monitored at
25 þ 0.1‡C.
2.5. Measurement of translocation
Symmetrically labelled LUVs were prepared by
hydrating the lipid ¢lm composed of POPC, POPG
and DNS-PE (70:15:15 mol/mol/mol). The observa-
tion of the £uorescence intensity of the Trp residue
(328 or 335 nm) upon excitation at 280 nm allows to
monitor the resonance energy transfer (RET) from
the Trp residue of the peptide to the dansyl £uoro-
phore in the membrane. The temperature was con-
trolled at 25 þ 0.1‡C.
2.6. Dithionite ion permeability
A lipid ¢lm composed of POPC/POPG/NBD-PE
(7:3:0.05 mol/mol/mol) was resuspended with the
bu¡er and freeze-thawed for ¢ve cycles. Small ali-
quots of the multilamellar vesicles (MLVs) were
added to the bu¡er (control) or injected into a pep-
tide solution in the presence of 10 mM sodium di-
thionite (freshly prepared at 1 M in 1 M Tris, pH
8.8). The £uorescence intensity of NBD at 530 nm
(excited at 450 nm) was monitored at 25 þ 0.1‡C.
2.7. Circular dichroism (CD) measurement
Peptide CD spectra were obtained on a Jobin
Yvon CD6 spectropolarimeter. The spectra were
scanned at room temperature in a quartz optical
cell of 0.02 cm path length. Baseline spectra for
each solvent or vesicle suspension were obtained pri-
or to the peptide spectra. Each peptide was at a
BBAMEM 78206 24-1-02
G. Drin, J. Temsamani / Biochimica et Biophysica Acta 1559 (2002) 160^170162
concentration of 75U1036 M in bu¡er (150 mM
NaF, 20 mM Tris, 0.1 mM EDTA), in TFE/bu¡er
mixture (v/v 1:1) or in presence of SDS (0.5%). To
measure spectra with SUVs, the concentration of
peptide was decreased to 50U1036 M31 to ensure
complete saturation of peptides with SUVs and to
reduce the absorption and di¡usion caused by the
presence of phospholipid vesicles. When the peptide
adopted a preferential helical structure, the helical
content was determined from the mean residue ellip-
ticity [3] at 222 nm according to the relation
3 222  330300K 32340
where [K] is the amount of helix [24].
2.8. Flow cytometry of cell-association of peptide
K562 cells were cultured in RPMI supplemented
with 10% foetal bovine serum. Cells were diluted at
0.3U106 cells ml31 1 day before the experiment. Cell
association was measured by £ow cytometry using a
FACSCalibur (Becton Dickinson, USA). TMR-la-
belled peptides (1 WM) were incubated with K562
cells (5U105 cells per ml) in Opti-MEM medium at
37‡C for various periods of time (¢nal volume was
0.5 ml). Thereafter, the cells were washed twice and
then resuspended in 0.5 ml of ice-cold PBS for FACS
analysis. Cell-associated £uorophores were excited at
488 nm and the £uorescence of TMR was measured
at 575 nm. A histogram of £uorescence intensity per
cell (1U104) was obtained and the calculated mean
of this distribution was considered as representative
of the amount of cell-associated peptides.
3. Results
3.1. Design and secondary structure of peptides
To measure the interaction of native PG-1 with
phospholipidic vesicles and its translocation ability,
we synthesised a £uorescent analogue termed
[12W]PG-1 (Fig. 1). This peptide corresponds to
PG-1 in which an aromatic residue (Phe) located at
position 12 was substituted by a similar but £uores-
cent residue (Trp). We then designed a linear ana-
logue named PG-AL deriving from [12W]PG-1 by
substituting all Cys residues involved in disulphide
bridges by either alanine or leucine. These residues
(Ala at position 6 and 13, Leu at position 8 and 15)
were carefully chosen in order to have a linear ana-
logue of [12W]PG-1 with a similar theoretical hydro-
phobicity. For both peptides, we have calculated the
mean residue hydrophobicity GHf according to Eisen-
berg et al. [25] and using the hydrophobicity scale of
Wimley and White [26]. The PG-AL associated to a
calculated GHf value equal to 0.52 is theoretically
slightly more hydrophobic than [12W]PG-1
Fig. 1. Primary sequence of PG-1, [12W]PG-1, PG-AL and
SynB1.
Fig. 2. CD spectra of PG-1, [12W]PG-1 and PG-AL peptides in
bu¡er. Each peptide was used at a concentration of 75 WM in
bu¡er (20 mM Tris, 150 mM NaF, 0.1 mM EDTA, pH 7.4).
Solid line, PG-1; dotted line, [12W]PG-1; dashed line, PG-AL.
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(GHf= 0.47). The reference peptide SynB1 is associ-
ated to a GHf value equal to 0.33.
We checked the secondary structure of [12W]PG-1
by recording its CD spectrum as well as that of PG-1
in bu¡er. The spectrum of both peptides showed a
minimum around 200 nm and a maximum at 230 nm
(Fig. 2), characteristic of a L-hairpin structure [9].
The slight di¡erence in conformation and/or CD
contribution of di¡erent aromatic groups in PG-1
and [12W]PG-1 could explain the small di¡erence
in curve intensities and shapes observed between
the two spectra [27]. As expected, the PG-AL peptide
adopts a random coil conformation as indicated by
its CD spectrum that exhibited a minimum at 198
nm (Fig. 2).
3.2. Cell uptake of peptides
We incubated the £uorescent TMR-peptides with
K562 cells at 1 WM for various times at 37‡C to
measure the kinetics of cell uptake of peptide by
£ow cytometry. Fig. 3 shows that the kinetics of
cell-uptake of linear peptides SynB1 and PG-AL
reach a plateau after 1 h and indicate that PG-AL
is better internalised than SynB1. The cell uptake of
[12W]PG-1 was somewhat di¡erent since it did not
reach a ¢nal plateau, even after 2 h. In addition, we
observed that a large number of cells becoming non-
viable after incubation with high concentrations (3
WM) of this cyclised peptide.
3.3. Peptide interaction
The change of Trp £uorescence emission spectra
upon binding to phospholipid vesicles has been
widely used to demonstrate the interaction of pep-
tides with phospholipids [27,28]. Fig. 4A,B show, for
both peptides, a blue-shift of the wavelength of max-
imum £uorescence emission when POPC/POPG
(70:30 mol/mol) LUVs were added to the peptide
solution, indicating that both peptides interacted
Fig. 3. Cell uptake of peptides into K562 cells. Each TMR-pep-
tide was incubated with K562 cells at 1 WM in Opti-MEM for
various times at 37‡C. Each value represents the average of
triplicate experiments. Error bars correspond to þ S.D. (E)
TMR-SynB1, (a) TMR-PG-AL, (b) TMR-[12W]PG-1.
Fig. 4. Interaction of peptides with phospholipidic vesicles. Fluorescence emission spectra of [12W]PG-1 (A) and PG-AL peptide (B)
were recorded (excitation at 280 nm) in the absence or presence of 32, 64, 96 or 128 WM LUVs (POPC/POPG 70:30 mol/mol). The
peptide concentration was 1 WM. (C) Wavelength of the maximum £uorescence intensity emission represented as function of the lipid-
to-peptide molar ratio. (b) [12W]PG-1, (a) PG-AL.
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with the membranes. We have plotted the wavelength
corresponding to the maximum £uorescence intensity
of Trp residue as function of the lipid-to-peptide
molar ratio (Fig. 4C) to indicate that a major frac-
tion of [12W]PG-1 and PG-AL peptides was in a
lipid-bound form at a L/P value of 60 and 130, re-
spectively. It should be noted that the blue-shift ob-
served with [12W]PG-1 is accompanied by a decrease
in the £uorescence intensity of Trp residue. In con-
trast, the £uorescence intensity of PG-AL peptide
increases upon binding to vesicles.
3.4. Permeabilisation
A dye release assay was performed to examine the
membrane permeabilising activity of both peptides.
It was measured by an increase in £uorescence inten-
sity due to relief from the self-quenching of calcein
concentrated (70 mM) within the LUVs (data not
shown). The relationship between apparent percent
leakage value and the peptide-to-lipid molar ratio is
reported in Fig. 5 and shows that [12W]PG-1 induces
Fig. 5. Membrane-permeabilising activity of [12W]PG-1 and
PG-AL peptide. The leakage of calcein entrapped into LUVs
(POPC/POPG 70:30 mol/mol) was measured 5 min after addi-
tion of [12W]PG-1 (b) or PG-AL (a). The apparent percent
leakage value (% permeabilisation) was plotted against the pep-
tide-to-lipid molar ratio. Each value represents the average of
triplicate experiments. Error bars correspond to þ S.D.
Fig. 6. Detection of the peptide translocation. The peptides [12W]PG-1 (A) and PG-AL (B) were mixed with dansyl-LUVs (POPC/
POPG/DNS-PE 70:20:10) at time zero. The peptide and lipid concentrations were 1 and 115 WM, respectively. The £uorescence of
Trp at 335 nm (excitation at 280 nm) was recorded. The peptide binding to the vesicles is re£ected by the decrease of the intensity
from F0 to F1 due to RET. At various incubation times (30 s, 1, 2, 5, 10 min, traces 2^6), a large excess (¢nal concentration 730 WM)
of a second population of dansyl-free LUVs (POPC/POPG 70:30) was added as indicated by the arrows. An increase in intensity indi-
cates the relief from RET caused by the redistribution between the two vesicle populations of the peptide molecules which had been
bound to the outer surface of the ¢rst vesicle. The di¡erence (as labelled by vF) between ¢nal £uorescence intensity (F2) and the £uo-
rescence intensity (F2P) when both populations of vesicles were simultaneously added at time zero indicates the fraction of peptide
which has translocated into the inner lea£et during the incubation time. The trace is representative of ¢ve independent measurements.
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a leakage of calcein from vesicles at very low peptide-
to-lipid molar ratio. In contrast, PG-AL only perme-
abilises the membranes e¡ectively at very high P/L
values.
3.5. Peptide translocation
The translocation was detected according to the
protocol described by Matsuzaki et al. [18^21] based
on the evaluation of the amount of untranslocated
peptides remaining in the outer lea£et of the mem-
branes. The untranslocated peptides can be readily
removed from the vesicle surface by extraction with
a large excess of a second population of vesicles. The
resonance energy transfer (RET) from the Trp resi-
due of the peptide to the dansyl chromophore (DNS-
PE) incorporated into the membrane of the ¢rst pop-
ulation of vesicles allows determination of the unre-
movable (i.e., translocated) fraction. At time zero,
when dansyl-labelled vesicles (115 WM) were added
to a peptide solution (1 WM), a decrease in Trp £uo-
rescence was seen indicating RET due to peptide
binding to the membrane (Fig. 6A). After 1 min of
incubation, a second population of dansyl-free
vesicles (DNS-PE was substituted by POPG) was
added in large excess (more than 5-fold). The peptide
molecules, which had been bound to the outer lea£et,
were redistributed between the two vesicle popula-
tions, resulting in a relief from RET and in a fast
increase in the £uorescence intensity. In the case of
[12W]PG-1, the increased £uorescence intensity was,
however, smaller than the intensity obtained when
both vesicle populations were simultaneously added
to the peptide solution at time zero (as indicated by
vF). In addition, the ¢nal £uorescence decreased
with the incubation time, suggesting that a fraction
of the peptides became progressively unexposed to
the outer lea£et and therefore untransferable to the
second vesicles. This indicates a time-dependent pep-
tide translocation. It should be noted that the slow
increase of £uorescence observed after addition of
the second vesicle population could be attributed to
the cross-back of peptides through the membrane of
the ¢rst vesicle population [18,19,21]. The transloca-
tion assay performed with PG-AL showed that no
change of £uorescence was observed as a function
of time (Fig. 6B). This indicates that PG-AL remains
on the outer lea£et of the ¢rst population of vesicles
and does not translocate through the phospholipid
bilayer.
The [12W]PG-1 peptide is entirely protected from
the enzymatic action of trypsin as measured by RET
at 510 nm in presence of DNS-PE containing vesicles
(data not shown). This protection against trypsin
treatment, previously observed for tachyplesin I
[18], did not allow us to investigate the existence of
the [12W]PG-1 translocation through the lipid mem-
brane according to the protocol of Matsuzaki et al.
[19,21]. We therefore con¢rmed the translocation of
[12W]PG-1 by using a dithionite-permeability assay
[20,21]. Fig. 7 shows that the addition of sodium
dithionite, a membrane-impermeable compound, to
NBD-PE containing MLVs irreversibly quenches
the £uorophore localised on the outermost lea£et
(i.e., 15% of the initial NBD £uorescence). The addi-
tion of [12W]PG-1 allowed the reducing ion to react
with more than 85% of the NBD group within 6 min.
If the peptide had permeabilised only the outermost
bilayer, the reagent could have reacted with the £uo-
rophore facing the ¢rst interlamellar space, resulting
in a quenching less than 75% [20,21]. This suggests
that the [12W]PG-1 molecule ¢rst translocates across
Fig. 7. Detection of [12W]PG-1 translocation. Small aliquots of
MLVs composed of POPC/POPG/NBD-PE (70:30:0.5) were
added to bu¡er (trace 1) or to [12W]PG-1 solution (trace 2) in
the presence of the 10 mM sodium dithionite. The membrane-
impermeant S2O234 quenches irreversibly NBD £uorescence by
chemical reduction. The £uorescence at 530 nm (excitation at
450 nm) was normalised to the initial £uorescence in the ab-
sence of dithionite. [Lipids] = 42 WM; [Peptide] = 3 WM.
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the outermost bilayer and then destabilises the inner
bilayer.
3.6. Correlation between translocation and membrane
permeabilisation
Fig. 8 shows a comparison between the kinetics of
membrane permeabilisation induced by the
[12W]PG-1 and the kinetics of translocation of this
peptide determined at the same L/P value of 115. To
evaluate the percent translocation value, we used the
£uorescence intensity measured 60 s after the addi-
tion of dansyl-free vesicles (Fig. 6A). The peptide
translocation is coupled with the pore formation es-
timated from the apparent dye release value, suggest-
ing that [12W]PG-1 crosses the membrane by a pore
formation^translocation mechanism.
3.7. Secondary structure of peptides in several
environments
CD spectroscopy was used to determine the sec-
ondary structure of the peptides in several media.
Fig. 9A shows that TFE (50% w/v in bu¡er) induces
a slight modi¢cation of the spectrum of the
[12W]PG-1 peptide, with a shift of the negative
band from 200 towards 203 nm and an increase in
the intensity of the signal at 229 nm. This could
re£ect the modi¢cation of the hydrogen-bonding pat-
tern of the peptide in an apolar medium. In the pres-
ence of micelles of SDS, there was a slight displace-
ment of the negative band from 200 towards 205 nm,
a slight displacement of the positive band at 229 nm
and the appearance of a positive band at 190 nm.
These modi¢cations are compatible with an increase
in the L-sheet content of [12W]PG-1. Finally, in the
Fig. 9. CD spectra of [12W]PG-1 (A) and PG-AL (B) peptides in di¡erent media. CD spectra (b) in bu¡er (20 mM Tris, 150 mM
NaF, 0.1 mM EDTA, pH 7.4), (P) in TFE (v/v 1:1) 50%, (F) in the presence of SDS micelles at a SDS-to-peptide molar ratio value
of 150 with a peptide concentration at 150 WM, and (E) in the presence of POPC/POPG (70:30 mol/mol) SUVs with an L/P value of
160 (the peptide and lipid concentration were equal to 50 WM and 16.3 mM, respectively).
Fig. 8. Relationship between pore formation and peptide trans-
location for [12W]PG-1. The pore formation was estimated on
the basis of the dye release from POPG/POPC (70:30 mol/mol)
LUVs (L/P = 115). The peptide and lipid concentration were the
same as those for Fig. 6A. The fraction of translocated peptide
was evaluated according to 100UvF/(F2P3F1) from Fig. 6A.
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presence of POPC/POPG (70:30 mol/mol) SUVs, we
report changes of the CD spectrum similar to those
observed in the presence of SDS. As indicated pre-
viously in Fig. 2, the PG-AL peptide has no ordered
secondary structure in bu¡er. In the presence of
TFE, the CD spectrum of peptide showed minima
at 208 and 222 nm and a maximum at 193 nm, char-
acteristic of a right-handed K-helical conformation
(Fig. 9B). From the ellipticity value at 222 nm (see
Section 2), we evaluated the helical content of pep-
tide to 45.4%. We have also investigated the second-
ary structure of the peptide in the presence of SDS
micelles or upon binding to lipid vesicles and we
show that it adopts preferentially a helical conforma-
tion with, respectively, a helical content of 21% and
26% (Fig. 9B).
4. Discussion
We have investigated whether protegrin (in a £uo-
rescent form) and a linear analogue PG-AL are able
to pass across a lipid bilayer. This study allows us to
better understand the relationship between the fold-
ing of protegrin and its permeabilisation mechanism
upon binding to lipidic membranes. In addition, this
study has provided information about the mode of
cell uptake of SynB peptides derived from PG-1 by
linearisation [11]. It has been previously proposed
that the cell uptake of peptides such as penetratin
or transportan occurs by crossing the lipid matrix
of plasma membranes in an energy-independent
manner [29,30]. Thus, our studies allow us to evalu-
ate whether the cell uptake of peptides derived by
linearisation of protegrin depends on their transloca-
tion through the lipid matrix of the plasma mem-
brane.
We have synthesised a £uorescent analogue of pro-
tegrin PG-1, named [12W]PG-1, following the syn-
thesis protocol used previously to produce the prote-
grin [4,6]. The substitution of residue Phe by Trp at
position 12 within the primary sequence does not
a¡ect the formation of the L-hairpin turn and disul-
phide bridge formation, as indicated by the similarity
between the CD spectra recorded for PG-1 and
[12W]PG-1. The spectra obtained were similar to
those reported earlier for native PG-1 [9]. As ex-
pected, the PG-AL peptide, a linear analogue of
[12W]PG-1, has no de¢ned secondary structure, con-
¢rming that the two disulphide bridges are crucial for
stabilising the protegrin folding.
By using £ow cytometry, we have compared the
internalisation of PG-AL and [12W]PG-1 into
K562 cells to our reference peptide SynB1 [11^13].
The cell-uptake of PG-AL and SynB1 exhibits a sim-
ilar kinetic pro¢le, whereas that of [12W]PG-1 is dif-
ferent. This result indicates ¢rst that PG-AL is rep-
resentative of the SynB family in term of cell-uptake
and suggests that the linear and cyclised peptides
enter into cells by a di¡erent mechanism. This was
illustrated by the observation made during internal-
isation assay indicating that only the [12W]PG-1 in-
duced cell death when its concentration was slightly
increased (data not shown). Therefore, it is very dif-
¢cult to compare the internalisation of PG-AL and
[12W]PG-1 since for this latter peptide, cell viability
might be a¡ected. At opposite, we propose that the
strong internalisation of PG-AL compared to those
of SynB1 could be due to its higher hydrophobicity,
since we have demonstrated that this physico-chem-
ical property could govern the cell uptake of linear
peptidic vectors [31].
We have studied the interaction of [12W]PG-1 and
PG-AL with membranes containing 30% (mol/mol)
negatively charged phospholipids. The interaction of
both peptides with the lipid bilayers was monitored
by the blue-shift in Trp £uorescence emission spectra
due to the re-localisation of this residue from a polar
to a hydrophobic environment. The interaction be-
tween [12W]PG-1 and lipids was strong as indicated
by the low L/P for which we observed a complete
saturation of peptide by vesicles. Compared to
[12W]PG-1, the PG-AL peptide seems to have a low-
er lipid-binding a⁄nity, suggesting that the folding
of protegrin favours its interaction with phospholip-
ids.
Using a dye release assay, we have shown that
[12W]PG-1 induces permeabilisation of membranes
at high lipid-to-peptide molar ratio (L/P = 125 for
75% permeabilisation) consistent with a permeabilis-
ing mechanism involving the formation of pores
[6,7]. Circular dichroism spectra suggest that the L-
sheet content of [12W]PG-1 increases upon binding
to phospholipid vesicles or in the presence of SDS
micelles. This observation agrees with 1H NMR re-
sults reported by Roumestand et al. [8] who pro-
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posed previously that PG-1 in dodecylphosphocho-
line micelles is better structured than in water. Thus,
the formation of a multimeric pore could depend on
the slight rearrangement of the L-hairpin structure of
protegrin. In addition, an unusual quenching of Trp
£uorescence was observed when the peptides inter-
acted with lipids. One explanation could be that
this quenching is due to the close contact between
the Trp residue of a [12W]PG-1 monomer and an
amino acid belonging to a second one.
The linear analogue of [12W]PG-1 probably does
not form pores, as indicated by its low permeabilis-
ing activity observed at low lipid-to-peptide molar
ratios. In addition, cytotoxicity assays carried out
with K562 cells incubated with peptides for 48 h
(Mazel et al., unpublished data) indicate that the
PG-AL peptide is 4-fold less cytotoxic than
[12W]PG-1 and PG-1 (these latter two peptides
have the same cytotoxicity). This could re£ect the
fact that PG-AL has a lower permeabilising potential
against natural membranes than [12W]PG-1.
We have assayed the translocation of [12W]PG-1
according to the protocol previously described by
Matsuzaki et al. [18^21]. We report here that
[12W]PG-1 translocates rapidly from the outer to
the inner lea£et of phospholipid bilayer at a high
lipid-to-peptide molar ratio. In contrast, the PG-
AL peptide does not cross the membrane indicating
that the linearisation of [12W]PG-1 suppresses its
permeabilising potency as well as its ability to trans-
locate through a lipid bilayer. This agrees with pre-
vious observations demonstrating that a linear ana-
logue of tachyplesin, forming a L-sheet at the surface
of the phospholipidic bilayer, is not able to pass
across membranes [18]. In our study, circular dichro-
ism indicates that, although PG-AL adopts a partial
helical conformation in an K-helical promoting me-
dium such as TFE, it has no predominant conforma-
tion in a membrane-mimetic environment or upon
binding to lipid vesicles. The folding of the protegrin
in a L-hairpin, stabilised by disulphide bridges, seems
to be a clear determinant for its ability to cross phos-
pholipid membranes.
The translocation of [12W]PG-1 is coupled to its
permeabilisation activity, suggesting that protegrin is
redistributed between the two lea£ets after the for-
mation of a transient pore in the membrane. It
should be noted that the translocation observed for
[12W]PG-1 and previously for TA-1 [18] occurs at a
similar L/P value in the presence of vesicles having a
similar phospholipid composition. In addition, the
dynamic behaviour of protegrin during pore forma-
tion and pore deactivation is consistent with the co-
existence of two states of protegrin in the phospho-
lipid bilayer corresponding to a surface-absorbed
state and a membrane-spanning state [9]. Moreover,
recent X-ray di¡raction studies have suggested that
protegrin forms a toroidal pore in the membrane
[32]. The peptide magainin has also been shown to
form toroidal pores, i.e., a multimeric organisation
constituted by heads of lipids and peptides localised
at the lipid/water interface [33]. In this model, the
lea£ets of the bilayer fold over onto each other, pro-
ducing a pore which looks like the inside of a torus
lined with peptides (‘wormhole’ model). It was
clearly demonstrated that magainins are able to
translocate across membranes [19,34]. Thus, our
data support the view that PG-1 interacts with and
translocates through the lipid membranes following
the ‘wormhole’ model.
The membrane permeabilisation mechanism of
protegrin seems to correspond to the model proposed
for tachyplesin and other peptides by Matsuzaki [34].
We demonstrate that this property of PG-1 depends
on its secondary structure, meaning that the linear
analogues derived from this peptide cannot sponta-
neously cross a lipid membrane. Thus, we propose
that the linearisation of PG-1 generates peptidic vec-
tors which are able to interact with the cellular mem-
branes but which cannot pass through their lipidic
matrix. The results obtained by the internalisation
assays suggest that the linear and disul¢de bridged
analogues of PG-1 have a di¡erent mode of cell up-
take. Therefore, this could mean that the penetration
of these linear peptides into intact cells depends on
an energy-dependant pathway. A recent work sup-
ports this view by indicating that the internalisation
of SynB1 into the endothelial cells of the blood^
brain barrier may involve adsorptive mediated endo-
cytosis [13]. However, we cannot exclude the possi-
bility that the cell uptake of SynB peptides involves,
in part, an unexplained energy-independent pathway,
as observed for other cationic peptidic vectors [35].
Our continuing studies are aimed at better under-
standing the cellular import of linear analogues of
protegrin.
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